ABSTRACT

Sofosbuvir is a newer antiviral drug candidate that well inhibits nucleotide polymerase virus. It can be given in the treatment of hepatitis C virus but it cannot prevent spread of the same to other people. Several ideal properties like limited daily dosing, less side effects, fewer drug-drug interactions, minimal drug resistance make this drug safer for the use. Ledipasvir is also a newer drug that was developed by Gilead Sciences and can be used in the treatment of Hepatitis C virus. This drug is an active inhibitor of hepatitis virus C protein NS5A. Common side effects of both these drugs include fatigue and headache. When combination of Sofosbuvir and Ledipasvir taken in a fixed dose, hepatitis C virus of genotypes 1, 4, 5, and 6 can be well prevented. Sofosbuvir-Ledipasvir therapy has been found to be safe and effective in the treatment of patient affected with hepatitis C virus. In this review, we have included several HPLC and RP-HPLC methods on Sofosbuvir and Ledipasvir either individually or in combination with another drug agent. Key words: Hepatitis, Sofosbuvir, Ledipasvir, HPLC, RP-HPLC, UPLC
Publication date: 01/11/2023

https://ijbpas.com/pdf/2023/November/MS_IJBPAS_2023_7585.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.11.7585